Find, compare & contact
Urokinase API Manufacturers & Suppliers

Looking for Urokinase API 9039-53-6?

Description:

Here you will find a list of producers, manufacturers and distributors of Urokinase. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Urokinase 

Synonyms:

U-plasminogen activator , uPA  

Cas Number:

9039-53-6 

DrugBank number:

DB00013 

Unique Ingredient Identifier:

83G67E21XI

Urokinase is a type of Thrombolytics

Thrombolytics, a subcategory of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in the field of medicine, particularly in the treatment of thrombotic disorders. Thrombolytics are highly effective in dissolving blood clots that form within blood vessels, thereby restoring blood flow and preventing potential complications.

These pharmaceutical agents work by activating the body's natural fibrinolytic system, which is responsible for breaking down fibrin, a protein involved in clot formation. Thrombolytics primarily target specific components of the clot, such as plasminogen, and convert them into active enzymes called plasmin. Plasmin subsequently degrades fibrin, leading to clot dissolution.

The therapeutic application of thrombolytics is vast, encompassing conditions like acute myocardial infarction (heart attack), deep vein thrombosis, pulmonary embolism, and ischemic stroke. Rapid administration of these APIs is critical to maximize their effectiveness and minimize the risk of complications.

Thrombolytics are available in various forms, including injectable formulations that can be administered intravenously or directly at the site of clot formation. Different thrombolytic agents, such as alteplase, tenecteplase, and reteplase, possess unique pharmacokinetic profiles and varying abilities to dissolve clots.

It is crucial to note that thrombolytics require careful monitoring and should be administered under the guidance of medical professionals due to potential adverse effects, such as bleeding complications. Therefore, their usage is strictly regulated, and patient-specific factors are considered before initiating thrombolytic therapy.

In summary, thrombolytics are an essential subclass of pharmaceutical APIs that effectively dissolve blood clots, restoring blood flow and preventing complications associated with thrombotic disorders. Their therapeutic application spans various medical conditions, and their administration should be carefully managed to ensure patient safety.

Urokinase (Thrombolytics), classified under Anticoagulants

Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.

There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.

Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.

While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.

In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.

• Kraeber & Co GmbH from Germany, product country of origin Germany

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.